secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001641172-25-003232
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma adopts 2025 Equity Incentive Plan with 1.5M initial shares
---------------------------------------------------------------------------

- Plan effective March 31, 2025; shareholder approval required under Nasdaq rules.
- Initially authorizes 1,500,000 shares of common stock for awards.
- Annual increase on Jan 1 each year: 5% of outstanding shares, up to 2,500,000 per year (total cap 4,000,000).
- Plan expires March 31, 2035; awards can include options, SARs, restricted stock, RSUs, performance shares/units, cash.
- No specific officer/director grants announced; plan is broad-based for employees, consultants, directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225003232/0001641172-25-003232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225003232/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-003232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer